Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Corporate Communications and IR John Butler - President and Chief Executive Officer Nicholas Grund - Chief Commercial Officer Conference Call Participants Ed Arce - H.C. Wainwright Julian Harrison - BTIG Operator Hello, and welcome to the Akebia's First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mod ...

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non- recurring items. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.05 per share when it actually produced break-even earnings, delivering a surprise of 100%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Akebi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ Commission File Number 001-36352 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-8756903 ( ...

Exhibit 99.1 Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Akebia to host conference call at 8:00 a.m. ET on May 9 • Vafseo® (vadadustat) tablets FDA approved on March 27, 2024 • Vafseo launch activities underway with availability expected in January 2025 • Auryxia® (ferric citrate) net product revenues were $31.0 million for the first quarter 2024, Akebia expects 2024 Auryxia net product revenue growth versus 2023 CAMBRIDGE, Mass.—May 9, 2024—Akebia Therape ...

Akebia to Host Conference Call on May 9, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 9, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call by phone, please click on this Regi ...

Key Points Akebia Therapeutics is a biotech specializing in treatments for chronic kidney diseases (CKD). Its lead drug, Vafseo, received FDA approval for treating anemia in adult CKD patients who have at least 3 months of dialysis. Vafseo is an oral tablet that has been approved in 37 countries. 5 stocks we like better than Akebia Therapeutics Akebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management fo ...

公司概况 - Akebia Therapeutics, Inc.（Nasdaq: AKBA）是一家生物制药公司，旨在改善肾脏疾病患者的生活[1] - Akebia Therapeutics成立于2007年，总部位于马萨诸塞州剑桥市[3] 员工期权 - 公司于2024年3月28日向六名新员工授予了购买总计110,000股Akebia普通股的期权，作为这些员工进入公司就业的诱因[1] - 这些期权的行权价格为每股1.83美元，与授予日Akebia普通股的收盘价相等[2] - 期权将在四年内解锁，首年解锁25％的股份，其余75％的股份每季度解锁，前提是新员工继续在Akebia工作[2] - 每个期权有10年期限，受Akebia诱因奖励计划和股票期权协议的条款和条件约束[2]

Akebia Therapeutics公司新药Vafseo®批准上市 - Akebia Therapeutics公司宣布美国食品和药物管理局（FDA）已批准Vafseo®（vadadustat）片剂用于治疗患有慢性肾病（CKD）并至少接受三个月透析治疗的成年患者的贫血[1] - Vafseo是一种每日一次口服的缺氧诱导因子脯氨酸羟化酶（HIF-PH）抑制剂，通过激活对缺氧的生理反应来刺激内源性促红细胞生成素的产生，以管理贫血[1] Akebia公司的合作与商业化计划 - Akebia公司致力于为肾病患者提供创新治疗选择，通过与CSL Vifor等行业领先公司合作，计划推出Vafseo以成为成人透析患者的新口服标准治疗[4] - Akebia Therapeutics, Inc.发布了关于Vafseo的商业化计划和前景的前瞻性声明[35] 公司商标和行业数据 - Akebia Therapeutics, Inc.拥有Auryxia®和Vafseo®的注册商标[36] - 美国肾脏数据系统的数据报告显示肾脏疾病在美国的流行病学情况[37]

Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.09 per share when it actually produced a loss of $0.08, delivering a surprise of 11.11%. Over the last four quar ...

Potential vadadustat U.S. approval on PDUFA date of March 27, 2024 Strengthened balance sheet with $55.0 million term loan financing and $26.0 million in proceeds from ATM Reported 2023 Auryxia (ferric citrate) net product revenue of $170.3 million CAMBRIDGE, Mass., March 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full yea ...